famotidine has been researched along with Female Genital Neoplasms in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Markman, M | 2 |
| Kennedy, A | 2 |
| Webster, K | 2 |
| Peterson, G | 2 |
| Kulp, B | 2 |
| Belinson, J | 2 |
1 trial available for famotidine and Female Genital Neoplasms
| Article | Year |
|---|---|
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Topics: Adult; Aged; Aged, 80 and over; Clinical Protocols; Desensitization, Immunologic; Dexamethasone; Dip | 2000 |
1 other study available for famotidine and Female Genital Neoplasms
| Article | Year |
|---|---|
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Drug Ad | 1999 |